000135334 001__ 135334
000135334 005__ 20240522124406.0
000135334 0247_ $$2doi$$a10.1016/j.jdin.2024.02.019
000135334 0248_ $$2sideral$$a138623
000135334 037__ $$aART-2024-138623
000135334 041__ $$aeng
000135334 100__ $$aGracia Cazaña, Tamara$$uUniversidad de Zaragoza
000135334 245__ $$aReal-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab
000135334 260__ $$c2024
000135334 5060_ $$aAccess copy available to the general public$$fUnrestricted
000135334 5203_ $$aBackground: The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians. Objectives: To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer. Methods: We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis. Results: Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected. Limitations: Modest sample size and the retrospective nature of the study. Conclusion: Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.
000135334 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000135334 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000135334 700__ $$aRiera Monroig, Josep
000135334 700__ $$aIzu, Rosa
000135334 700__ $$aYanguas, Ignacio
000135334 700__ $$aLorda Espés, Marta
000135334 700__ $$aSánchez Salas, María Pilar
000135334 700__ $$aGarcía Gil, Miguel Fernando
000135334 700__ $$aNavarro Bielsa, Alba
000135334 700__ $$aAldea Manrique, Beatriz
000135334 700__ $$0(orcid)0000-0002-4350-401X$$aAlmenara Blasco, Manuel$$uUniversidad de Zaragoza
000135334 700__ $$aGarcía-Latasa de Araníbar, Francisco Javier
000135334 700__ $$aFuentelsaz, Victoria
000135334 700__ $$aMorales Callaghan, Ana$$uUniversidad de Zaragoza
000135334 700__ $$0(orcid)0000-0001-8789-6783$$aAra-Martín, Mariano$$uUniversidad de Zaragoza
000135334 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000135334 773__ $$g16 (2024), 66-71$$tJAAD International$$x2666-3287
000135334 8564_ $$s668597$$uhttps://zaguan.unizar.es/record/135334/files/texto_completo.pdf$$yVersión publicada
000135334 8564_ $$s2329861$$uhttps://zaguan.unizar.es/record/135334/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000135334 909CO $$ooai:zaguan.unizar.es:135334$$particulos$$pdriver
000135334 951__ $$a2024-05-22-10:17:24
000135334 980__ $$aARTICLE